Showing results (1631-1640 of 3,194) with videos related to
Sort By:
Pageof 320
Translational Oncology|December 3, 2021
Chlorogenic acid: Potential source of natural drugs for the therapeutics of fibrosis and cancerEbuka-Olisaemeka Nwafor, Peng Lu, Ying Zhang, et al.Translational Oncology|December 5, 2021
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?Roberta Maltoni, Sara Ravaioli, Giuseppe Bronte, et al.Translational Oncology|September 21, 2022
Identification of a 5-gene-based signature to predict prognosis and correlate immunomodulators for rectal cancerLin Yi, Ji Qiang, Peng Yichen, et al.Translational Oncology|September 2, 2022
Comprehensive analysis to identify the RP11-478C19.2/ E2F7 axis as a novel biomarker for treatment decisions in clear cell renal cell carcinomaKai Zeng, Guoda Song, Bingliang Chen, et al.Translational Oncology|September 10, 2022
Circular RNA 0010117 promotes aggressive glioblastoma behavior by regulating the miRNA-6779-5p/SPEN axisXuanyong Yang, Yue Liu, Xinhui Zhou, et al.Translational Oncology|December 15, 2021
Sertraline repositioning: an overview of its potential use as a chemotherapeutic agent after four decades of tumor reversal studiesJoão Luiz Baú-Carneiro, Isabela Akemi Guirao Sumida, Malu Gallon, et al.Translational Oncology|December 10, 2021
Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expressionYueh-Te Lin, Joseph Lin, Yi-En Liu, et al.Translational Oncology|December 13, 2021
Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapyXiao-Hong Chen, Ruo Chen, Ming-Yan Shi, et al.Translational Oncology|January 1, 2022
PLK1 inhibition-based combination therapies for cancer managementShengqin Su, Gagan Chhabra, Chandra K Singh, et al.Translational Oncology|January 2, 2022
NCI's publication affiliation conundrum: Reframing innovation to incentivize an equitable path for advocate representationSusan Samson, Jason J Northey, Irene Acerbi, et al.Pageof 320